
GH Stock Forecast & Price Target
GH Analyst Ratings
Bulls say
Guardant Health is expected to see increased demand and revenue growth due to their innovative liquid biopsy technology and growing partnerships with biopharmaceutical companies. Despite facing competition in the market, the company has shown strong financial performance and has a solid pipeline for future growth based on their recent achievements and plans for expansion. However, there are potential risks to consider, such as legal and regulatory challenges, which could impact their financial performance in the future.
Bears say
Guardant Health is currently experiencing a flurry of positive catalysts, including its recent FDA approval for G360CDx and inclusion in both the American Cancer Society and NCCN guidelines for colon cancer screening. However, our negative outlook stems from concerns over deceleration in Guardant's core product, Guardant360, as well as uncertainties around the sustainability of Shield's high pricing and volume growth. Additionally, the company's financials may face pressure as reimbursement for multi-cancer screening tests is set to be linked to the pricing of a competitor, lowering potential rates for Guardant's Shield test.
This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GH Analyst Forecast & Price Prediction
Start investing in GH
Order type
Buy in
Order amount
Est. shares
0 shares